| |
| |
|
| Insider
Information: |
Nussbaum Ran |
| Relationship: |
Director |
| City: |
Santa Monica |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
8,611 |
|
|
Indirect Shares
|
10,899,216 |
|
|
| Direct
Value |
$172,220 |
|
|
|
Indirect Value
|
$27,304,139 |
|
|
| Total
Shares |
10,907,827 |
|
|
| Total
Value |
$27,476,359 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -70.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Kite Pharma, Inc. |
KITE |
Director |
2017-10-03 |
0 |
2017-10-03 |
0 |
Premium* |
|
|
Arno therapeutics Inc |
ARNI |
10% Owner |
|
0 |
2013-01-25 |
382,858 |
Premium* |
|
|
Eloxx Pharmaceuticals Inc |
ELOX |
Director |
2018-03-21 |
0 |
2021-05-13 |
7,804,778 |
Premium* |
|
|
Arqule Inc |
ARQL |
Director |
2018-05-18 |
8,611 |
2020-01-16 |
0 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director |
|
0 |
2021-01-22 |
0 |
Premium* |
|
|
Keros Therapeutics, Inc. |
KROS |
Director, 10% Owner |
|
0 |
2022-11-29 |
1,226,412 |
Premium* |
|
|
Urogen Pharma Ltd. |
URGN |
Director |
2021-03-24 |
0 |
2022-10-21 |
1,485,168 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KROS |
Keros Therapeutics, Inc. |
Director |
– • • |
2022-11-29 |
4 |
OE |
$0.00 |
$1 |
I/I |
7,176 |
1,226,412 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-10-21 |
4/A |
OE |
$5.94 |
$285,114 |
I/I |
47,999 |
1,485,168 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-10-21 |
4 |
OE |
$5.94 |
$285,114 |
I/I |
47,999 |
1,481,927 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-06-16 |
4 |
OE |
$5.00 |
$11,055 |
I/I |
2,211 |
1,437,169 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-06-06 |
4/A |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,434,958 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-06-06 |
4 |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,433,928 |
0 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
Director |
– • – |
2021-05-13 |
4 |
B |
$1.35 |
$7,999,999 |
I/I |
5,925,925 |
616,592 |
2.1 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2021-03-25 |
4/A |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,431,717 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2021-03-25 |
4 |
OE |
$5.00 |
$11,055 |
I/I |
2,211 |
1,433,928 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2021-03-24 |
4 |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,465,199 |
0 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2021-01-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,576,881) |
0 |
0 |
- |
|
| KROS |
Keros Therapeutics, Inc. |
Director |
– • • |
2020-04-13 |
4 |
B |
$16.00 |
$6,999,984 |
I/I |
437,499 |
149,262 |
2.25 |
- |
|
| KROS |
Keros Therapeutics, Inc. |
Director |
– • • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,545,100 |
105,512 |
0 |
- |
|
| KROS |
Keros Therapeutics, Inc. |
Director |
– • • |
2020-04-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
751,908 |
|
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2020-01-16 |
4 |
D |
$20.00 |
$174,896,400 |
I/I |
(8,744,820) |
0 |
0 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2019-12-24 |
4 |
D |
$20.11 |
$2,922,003 |
I/I |
(145,301) |
2,088,816 |
0 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2019-12-24 |
4 |
OE |
$1.75 |
$2,922,000 |
I/I |
1,669,714 |
2,123,673 |
0 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2019-09-12 |
4 |
OE |
$1.75 |
$200,001 |
I/I |
114,286 |
1,723,115 |
0 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2019-06-27 |
4 |
B |
$9.75 |
$2,999,997 |
I/I |
307,692 |
36,923 |
2.1 |
- |
|
| ELOX |
Eloxx Pharmaceuticals Inc |
Director |
– • – |
2019-06-24 |
4 |
B |
$9.00 |
$1,800,000 |
I/I |
200,000 |
24,000 |
2.1 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,576,881 |
|
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2018-07-13 |
4 |
B |
$5.50 |
$999,999 |
I/I |
181,818 |
1,630,657 |
2.1 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2018-05-18 |
4/A |
B |
$3.29 |
$28,330 |
I/I |
8,611 |
8,611 |
2.1 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2018-05-18 |
4 |
B |
$3.29 |
$28,330 |
D/D |
8,611 |
8,611 |
2.39 |
- |
|
| ARQL |
Arqule Inc |
Director |
– • – |
2018-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
6,608,000 |
1,587,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
